Tofacitinib Is
a Mechanism-Based Inactivator of Cytochrome
P450 3A4
Posted on 2019-08-25 - 15:13
Tofacitinib
(TFT) is an oral JAK inhibitor which has been approved
for the treatment of moderately and severely active rheumatoid arthritis.
TFT was found to show concentration-, time-, and NADPH-dependent inhibition
of CYP3A4, and irreversibility of the inactivation was also observed.
Incubation (40 min, 37 °C) of recombinant CYP3A4 with TFT at
200 μM resulted in >70% loss of CYP3A4 activity. Estimated kinact and KI were
0.037 min–1 and 93.2 μM, respectively. GSH
and superoxide dismutase/catalase revealed minor or little protection
against the CYP3A4 inactivation. Furthermore, ketoconazole attenuated
TFT-mediated CYP3A4 inactivation. Epoxide and α-keto-aldehyde
intermediates of TFT were trapped and characterized in microsomal
incubations, respectively. The aldehyde intermediate is believed to
be the key for the enzyme inactivation. Multiple P450 enzymes, including
CYPs2C19, 3A4, 2D6, and 1A2, participated in the metabolism of TFT
to the epoxide, while the formation of the aldehyde was mainly catalyzed
by CYP3A4. In conclusion, TFT was proven to be a mechanism-based inactivator
of CYP3A4.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Guo, Xiucai; Li, Wei; Li, Qingmei; Chen, Yan; Zhao, Guode; Peng, Ying; et al. (2019). Tofacitinib Is
a Mechanism-Based Inactivator of Cytochrome
P450 3A4. ACS Publications. Collection. https://doi.org/10.1021/acs.chemrestox.9b00141
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (7)
XG
Xiucai Guo
WL
Wei Li
QL
Qingmei Li
YC
Yan Chen
GZ
Guode Zhao
YP
Ying Peng
JZ
Jiang Zheng